Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Indinavir 333mg capsules
0503010T0AAACAC
|
Indinavir | Indinavir | Infections | No data available |
|
Indinavir 400mg capsules
0503010T0AAAAAA
|
Indinavir | Indinavir | Infections | No data available |
|
Indocid 25mg capsules
1001010K0BDAAAA
|
Indocid | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indocid 50mg capsules
1001010K0BDABAB
|
Indocid | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indocid 5mg/ml oral suspension
1001010K0BDACAE
|
Indocid | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indocid PDA 1mg powder for solution for injection vials
0701011E0BBAAAA
|
Indocid (Neonatal) | Indometacin | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Indocid R 75mg capsules
1001010K0BDAFAD
|
Indocid | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indolar SR 75mg capsules
1001010K0BGADAD
|
Indolar | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indomax 75 SR capsules
1001010K0BQABAD
|
Indomax | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 1.2mg/5ml oral liquid
1001010K0AAATAT
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 12mg/5ml oral liquid
1001010K0AAAYAY
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 15mg/5ml oral liquid
1001010K0AAAZAZ
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 1mg powder for solution for injection vials
0701011E0AAAAAA
|
Indometacin (Neonatal) | Indometacin | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Indometacin 20mg/5ml oral liquid
1001010K0AAARAR
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 25mg modified-release capsules
1001010K0AAACAC
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 25mg modified-release tablets
1001010K0AAALAL
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 25mg/5ml oral suspension sugar free
1001010K0AAAEAE
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 31.25mg/5ml oral liquid
1001010K0AAAWAW
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 3mg/5ml oral liquid
1001010K0AAASAS
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 500micrograms/5ml oral liquid
1001010K0AAAUAU
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 50mg modified-release tablets
1001010K0AAAKAK
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indometacin 50mg/5ml oral liquid
1001010K0AAAVAV
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indomod 25mg modified-release capsules
1001010K0BIAAAC
|
Indomod | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Indomod 75mg modified-release capsules
1001010K0BIABAD
|
Indomod | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Industrial methylated spirit 95%
1311010A0AAAAAA
|
Industrial methylated spirit | Alcohol | Skin | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.